许 旭, 孙敬岩, 顾 林, 张丽娜, 张 宇, 付 丽. RAR-β2 基因在乳腺肿瘤组织中的表达及意义*[J]. 中国肿瘤临床, 2010, 37(2): 85-89. DOI: 10.3969/j.issn.1000-8179.2010.02.006
引用本文: 许 旭, 孙敬岩, 顾 林, 张丽娜, 张 宇, 付 丽. RAR-β2 基因在乳腺肿瘤组织中的表达及意义*[J]. 中国肿瘤临床, 2010, 37(2): 85-89. DOI: 10.3969/j.issn.1000-8179.2010.02.006
shu
XU Xu, SUN Jingyan, GU Lin, ZHANG Li’na, ZHANG Yu, FU Li. The Expression and Significance of RAR-β2 Gene in Breast Tumor[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 37(2): 85-89. DOI: 10.3969/j.issn.1000-8179.2010.02.006
Citation: XU Xu, SUN Jingyan, GU Lin, ZHANG Li’na, ZHANG Yu, FU Li. The Expression and Significance of RAR-β2 Gene in Breast Tumor[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 37(2): 85-89. DOI: 10.3969/j.issn.1000-8179.2010.02.006
shu

RAR-β2 基因在乳腺肿瘤组织中的表达及意义*

The Expression and Significance of RAR-β2 Gene in Breast Tumor

    摘要
  • 摘要: 目的：检测视黄酸受体β 2（RAR-β 2）基因在不同乳腺肿瘤组织中的表达，探讨RAR-β 2 基因与乳腺肿瘤的关系，分析其在乳腺癌发生、发展中的作用。方法：免疫组织化学法检测乳腺浸润性癌、导管上皮重度不典型增生、腺纤维瘤各40例及20例正常乳腺组织中RAR-β 2 的表达情况。RT-PCR 法检测乳腺浸润性癌、导管上皮重度不典型增生、腺纤维瘤及正常乳腺组织各20例RAR-β 2 的表达水平。结果：免疫组化结果显示，RAR-β 2 阳性表达主要位于细胞核，RAR-β 2 蛋白在乳腺浸润癌组织中阳性表达率（30.0%）明显低于正常乳腺组织（95.0%），χ2=26.30，P<0.05。RAR-β 2 蛋白在乳腺重度不典型增生组织中阳性表达率（17.5%）低于乳腺癌组织，但差异无统计学意义（P>0.05）。 在乳腺浸润性癌组织中，RAR-β 2 表达与患者年龄、肿瘤大小、临床分期、腋下淋巴结转移状况、组织学分级、病理学类型以及ER、PR表达状况无相关性（P 均>0.05）。 随访结果显示，28例RAR-β 2 阴性乳腺癌患者中3 例发生内脏转移，而12例RAR-β 2 阳性患者仅1 例发生骨转移。RT-PCR 结果显示，RAR-β 2 在乳腺癌、导管上皮重度不典型增生、腺纤维瘤及正常乳腺组织中阳性表达率分别为25.0%（5/20）、35.0%（7/20）、85.0%（17/20）和100%（20/20），乳腺癌组织RAR-β 2 mRNA 明显低于正常乳腺组织（χ2=30.43，P<0.001）。 结论：RAR-β 2 可能在乳腺癌的发生过程中发挥抑制作用，并且可能在乳腺癌发生的早期发挥作用。

     

    Abstract: Objective:To assess the expression of retinoic acid receptor beta 2 (RAR-β2) in breast tumor and to evaluate the relationship between RAR-β 2 expression and tumorigenesis of breast cancer.Methods: Immu -nohistochemistry was used to detect the expression of RAR-β 2 protein in specimens from 40cases of breast cancer,40cases of atypical ductal hyperplasia, 40cases of fibroadenoma and 20cases of normal breast tissues. Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the mRNA expression levels of RAR-β 2 gene in 20cases of breast cancer, 20cases of atypical ductal hyperplasia,20cases of fibroadenoma, and 20cases of normal breast tissues. Results:Immunohistochemical staining results revealed that the positive expression of RAR-β 2 protein showed nuclear staining. The positive expression rate of RAR-β 2 was 30% (12/40) in breast cancer, 17.5% (7/40) in atypical ductal hyperplasia, 87.5% (35/40) in fibroadenoma, and 95% (19/20) in normal breast tissues. The expression of RAR-β 2 protein in breast cancer was significantly lower than that in normal breast tissues (χ2=26.30, P<0.001 ). The expression of RAR-β 2 was not significantly different between atypical ductal hyperplasia and breast cancer ( P>0.05）. No correlation was found between the expression of RAR-β2 protein and the tumor size, menopausal age, lymph node metastasis, clinical stage, histological grade, or protein expression of ER and PR in breast cancer tissues ( P>0.05). Follow-up results showed that 3 out of 28patients with negative RAR-β 2 expression had visceral organ metastasis, but only one of the 12RAR-β 2 positive patients had osseous metastasis. RT-PCR analysis showed that the positive expression rate of RAR-β 2 mRNA in breast cancer, atypical ductal hyperplasia, fibroadenoma and normal breast tissues was 25% (5/20), 35% (7/20), 85% (17/20) and 100 % (20/20), respectively. The RAR-β2 mRNA expression rate in breast cancer was significantly lower than that in normal breast tissues ( χ2=30.43, P<0.001 ). No significant difference in RAR-β2 mRNA expression was found between atypical ductal hyperplasia and breast cancer tissues ( P>0.05). Conclusion: RAR-β2 gene may play a repressive role in the initiation of breast cancer, and the loss of the expression of RAR-β2 gene may be the initial step in breast carcinogenesis.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回